Medicamentos beta-agonistas de larga acción: perfil de riesgo-beneficio en pacientes con asma

Rodolfo J  Dennis

Medicamentos beta-agonistas de larga acción: perfil de riesgo-beneficio en pacientes con asma

Long-acting beta agonists: a risk-benefit profile in patients with asthm

Publicado 2010-06-01

Abrir | Descargar

PDF FLIP

Número

Vol. 22 Núm. 2 (2010)

Sección

Revisión de tema

Cómo citar

Dennis RJ. Medicamentos beta-agonistas de larga acción: perfil de riesgo-beneficio en pacientes con asma.

rev. colomb. neumol. [Internet]. 2010 Jun. 1 [cited 2025 May 22];22(2):37-41.

DOI

Licencia

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.

Rodolfo J Dennis

MD, MSc, PhDc. Director Departamentos de Medicina Interna e Investigaciones, Fundación Cardioinfantil. Profesor Titular de Medicina, Universidad Javeriana. Bogotá, Colombia.

Mostrar biografía de los autores

broncodilatadores

asma

riesgo

beneficio

revisión

Existe evidencia que muestra que pacientes asmáticos con exposición a broncodilatadores beta-agonistas de larga acción (BALA), en quienes no se garantiza el tratamiento controlador anti-inflamatorio simultáneo con corticoides inhalados (ICS), pueden presentar eventos de empeoramiento del asma muy infrecuentes, pero severos y potencialmente mortales. No es claro si este hallazgo puede ser debido a eventos adversos asociados con el mecanismo de acción de los BALA, o a enmascaramiento de la severidad del asma. No existe evidencia derivada de experimentos clínicos en seres humanos que sugiera que pacientes con exposición a BALA, en quienes se garantiza el tratamiento controlador anti-inflamatorio simultáneo con ICS, puedan presentar eventos severos de empeoramiento del asma potencialmente mortales. De igual forma, tampoco hay evidencia conclusiva de presencia de riesgo derivada de meta-análisis y de estudios observacionales. Desafortunadamente, tampoco existe evidencia conclusiva de ausencia de riesgo. El juicio de valor que se le asigna al balance de riesgo-beneficio de los BALA+CSI puede variar entre médicos, pacientes, reguladores, y epidemiólogos. Este balance ha sido discutido extensamente. En general, hay consenso que este balance está a favor de mantener disponible las combinaciones de BALA+CSI para los pacientes con
asma. En esta revisión se enuncian las principales recomendaciones con respecto a su utilización, basadas en la evidencia actual.

Visitas del artículo 86 | Visitas PDF 72

Descargas

Los datos de descarga todavía no están disponibles.

Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326: 501-6.
Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604-10.
Mullen M, Mullen B, Carey M. The association between betaagonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 1993; 270: 1.842-5.
Ernst P, Habbick B, Suissa S, et al. Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? Am Rev Respir Dis 1993; 148: 75-9.
Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA 1992; 268: 3462-42
Pearlman DS, Chervinsky P, La Force C, et al. A comparison of salmeterol with albuterol in the treatment of mild to moderate asthma. N Engl J Med 1992; 327: 1420-5.
D’Alonzo GE, Nathan RA, Henochowicz S, et al. Salmeterol Xinafoate as Maintenance Therapy Compared With Albuterol in Patients With Asthma. JAMA 1994; 271: 1412-6.
Salpeter SR, Ormiston TM, Salpeter EE. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004; 140: 802-13.
Sindi A, Todd DC, Parameswaran M. Anti-inflammatory effects of long-acting beta2-agonists in patients with asthma. Chest 2009; 136: 145-54.
Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study. BMJ 1993; 306: 1034-7.
Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter research trial. Chest 2006; 129: 15-26.
Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax 1997; 52: 612-7.
Lanes SF, Lanza LL, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med 1998; 158: 857-61.
Williams C, Crossland L, Finnerty J, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax 1998; 53:1-2.
Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 2005; 330: 117.
Drazen JM, O´Byrne PM. Risk of long-acting beta-agonists in achieving asthma control. N Eng J Med 2009; 360: 1671-2.
Wijesinghe M, Weatherall M, Perrin K, et al. International trends in asthma mortality rates in the 5 to 34 year age group. Chest 2009; 135: 1045-9.
Wijesinghe M, Perrin K, Harwood M, et al. The risk of asthma mortality with inhaled long acting beta-agonists. Postgrad Med J 2008; 84: 467-72.
Gyembycz MA, Kaur M, Leight R, et al. A holy grail of asthma management: toward understanding how long acting beta2 adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 2008; 153: 1090-1104.
Martinez FD. Safety of long-acting beta-agonists: an urgent need to clear the air. N Eng J Med 2005; 353: 2637-2639.
Beasley R, Martinez FD, Hackshaw A, et al. Safety of longacting beta-agonists: urgent need to clear the air remains. Eur Respir J 2009; 33:3-5
Taylor DR. On and on it goes-the beta agonist saga and its clinical relevance. Am J Respir Crit Care Med. 2009; 179:976-8.
Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest 2009; 136: 604-7.
Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with formoterol for chronic asthma: serious adverse events.Cochrane database syst rev 2008 (4): CD006923.
Sears MR, Ottosson R, Radner F et al. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33: 21-32.
Wijesinghe M, Weatherall M, Perrin K, et al.Risk of mortality associated with formoterol: a systematic review and metaanalysis. Eur Respir J 2009; 34: 803-811.
Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: combined analysis of data from randomized control trials. J Allergy and Clin Inmunol 2010; 125: 390-6.
Cates CJ, Cates MJ, Lasserson TJ. Regular treatment with salmeterol for chronic asthma: serious adverse events. Cochrane database syst rev 2008 (3): CD006363.
Bateman E, Nelson H, Bousquet J, et al. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 2008; 149: 33-42.
Weatherall M, Wijesinghe M, Perrin K, et al. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy. Thorax 2010; 65:39-43.
Salpeter SR, Buckely NS, Ormiston TM, et al. Meta-analysis: effect of long acting beta-agonists on severe asthma exacerbations and asthma related deaths. Ann Intern Med 2006;144: 904-912.
Jaeschke R, O´Byrne PM, Mejza F, et al. The safety of longacting beta-agonists among patients with asthma using inhaled corticosteroids.Am J Respir Crit Care Med 2008; 178: 10091016.
Rodrigo GJ, Plaza V, García L, et al. Safety of regular use of long-acting beta-agonists as monotherapy or added to inhaled corticosteroids in asthma. Pulmonary Pharmacology & Therapeutics 2009;22: 9-19.
Salpeter SR, Wall AJ, Buckley NS. Long-acting beta-agonists with and without inhaled corticosteroids and catastrophic asthma events. Am J Med 2010; 123:322-8.
Pauwels R, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Eng J Med 1997; 337: 1405-1411.
Lemanske RF, Sorkness CA, Mauger EA, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol. JAMA 2001; 285: 2594-2603.
O´Byrne PM, Barnes PJ, Rodriguez R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392-1397.
Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The GOAL study. Am J Respir Crit Care Med 2004; 170: 836-844.
Edwards SJ, von Maltzhan R, Naya IP, Harrison T. Budesonide/ formoterol for maintainance and reliever therapy of asthma. Int J Clin Practice 2010; 64: 619-27.
Lemanske RF, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Eng J Med 2010; 362: 975-985.
Dennis RJ, Solarte I, and Rodrigo G. Asthma in adults. Clin Evid (Online). 2010 Jan 21; 2010. pii: 1501.
Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2agonists versus antileukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. The Cochrane library, issue 2, 2008. John Wiley & Sons Ltd. Search date 2006.
Kramer JD. Balancing the benefits and risks of long-acting betaagonists – the influence of values. N Eng J Med 2009; 360:1592-1595.
The American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007;356:20272039.
Weatherall M, Wijesinghe M, Perrin K, Beasley R. Long-acting beta-agonists and asthma death: how useful are different study designs to evaluate the potential association? J Asthma. 2010;47:434-8.